CNH Equipment Helps Thai Rice Farmer Replace Stubble Burning
10 October 2026, Basildon, UK: CNH’s (NYSE: CNH) latest A Sustainable Year story, highlights how agricultural equipment …
Africa at the Forefront as MAHARISHI Opens Funded Millet Research Training in India
10 October 2026, Africa: As climate change intensifies drought, heat and rainfall variability across Africa, scientists …
19 Scaling Pathways: What Makes Innovation Stick?
10 October 2026, Africa: Proven agricultural innovations achieve lasting impact when farmers, businesses and public inst…
Getting Ahead of El Niño: Turning Early Warnings Into Action Across The Horn Of Africa
10 October 2026, Africa: When El Niño rains reach the drylands of the greater Horn of Africa, the first problems herders…
TERI and Meghalaya Energy Corporation Limited Sign MoU to Strengthen Meghalaya’s Renewable Energy Sector
10 October 2026, Shillong: The Meghalaya Energy Corporation Limited (MeECL) and The Energy and Resources Institute (TERI…
US spray drone market “very much in flux” as firms attempt to navigate evolving landscape, says ASDC
Ten months after the FCC’s bombshell decision to ban sales of new models of foreign made drones and critical components …
East Africa Foods Raises $40m To Scale Digital And Physical Food Supply Chains
1 East Africa Foods has raised approximately $40m, including a $26m Series B equity round led by PIDG, to expand its foo…
EU cosmetics face PFHxA limits as REACH transition ends
The EU restriction on the “forever chemical” undecafluorohexanoic acid (PFHxA) in cosmetics applies tomorrow.
AI personalization and longevity shape Indonesian beauty market
Indonesia’s beauty market is increasingly embracing holistic and individualized skin care through tech-enhanced personalization and multifaceted longevity care.
Newron plans heart tests to lift schizophrenia trial hold
Why it matters: Roughly a third of people with schizophrenia are treatment-resistant, and only about 40% of them respond to clozapine, the most effective antipsychotic used for this condition. Evenamide, Newron’s lead drug, is in two Phase 3 trials as an add-on for this group, and the company says it could become the first such treatment.